Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

by | Feb 20, 2026 | Clinical Trials | 0 comments

​ Conditions: Diabetes (DM); Type 2 Diabetes; Obesity (Disorder)

Interventions: Drug: Semaglutide (SEMA)

Sponsors: LMC Diabetes & Endocrinology Ltd.

Not yet recruiting Conditions: Diabetes (DM); Type 2 Diabetes; Obesity (Disorder)
Interventions: Drug: Semaglutide (SEMA)
Sponsors: LMC Diabetes & Endocrinology Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *